MedTrace Logo

First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer

NCT01163396 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2015-03-11

No results posted yet for this study

Summary

This is a single-arm, open-label, multicentre phase II study evaluating the safety and efficacy of the combination of the G.O.N.O. FOLFOXIRI regimen with bevacizumab as first-line treatment of metastatic colorectal cancer.

Conditions

  • Colorectal Cancer Metastatic

Interventions

DRUG

Bevacizumab

DRUG

Irinotecan

DRUG

Oxaliplatin

DRUG

5-fluorouracil/leucovorin

Sponsors & Collaborators

  • Gruppo Oncologico del Nord-Ovest

    lead OTHER

Principal Investigators

  • Alfredo Falcone, MD · University of Pisa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-04-30
Completion
2010-04-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01163396 on ClinicalTrials.gov